GTGim Gee Teng

Gim Gee Teng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gim Gee Teng has a total of 190 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Elevated Liver Enzymes Is Not an Impediment to Allopurinol Dose Escalation: An Observational Cohort Study

    by May Shuen Tang, Qai Ven Yap, Peter Pak Moon Cheung, Amelia Santosa, Gim Gee Teng

    Objective: Routine liver enzyme monitoring is advocated for while on allopurinol, but supporting guidance is lacking. We assessed the incidence and factors associated with elevated liver enzyme levels in patients with gout commenced on allopurinol. Methods: One hundred and fifty patients with gout and normal baseline serum aminotransferases initiated on allopurinol were followed prospectively over three visits. Raised transaminase levels were defined as mild, moderate, or severe if aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels were raised less than two, two to three, or more than three times above upper normal limits, respectively. Predictors of AST/ALT elevation were assessed using generalized estimating equations. Results: Mean age was 56.6 years, and 95.3% were men. Median follow‐up was 33.5 (interquartile range 22.8–53.1) weeks. A total of 32 (21.5%) drank alcohol, 43 (28.9%) were obese, and 11 (7.3%) had metabolic dysfunction–associated steatotic liver disease. Thirty (20.0%) developed raised AST/ALT levels during follow‐up, the majority (86.7%) being mild, while none were severe. Allopurinol was maintained or increased in 18 out of 19 patients with raised serum aminotransferase levels at visit 2. Their elevated AST/ALT levels remained stable (27.8%), improved (11.1%), or resolved (33.3%) at subsequent visit. None had worsening AST/ALT levels. Multivariate analysis revealed that alcohol consumption (adjusted odds ratio [OR] 3.52, 95% confidence interval [CI] 1.41–8.79) and statin nonuse (adjusted OR 3.41, 95% CI 1.04–11.17) were independent predictors of raised transaminase levels. Higher allopurinol dose was not associated with development of liver enzyme elevation ( P = 0.193). Conclusion: Mild asymptomatic AST/ALT elevation is common among patients with gout and is not influenced by allopurinol dose escalation. Alcohol consumption was an independent risk factor for elevated liver enzyme levels, whereas statin use appeared protective. Allopurinol can be safely escalated despite mild‐moderate serum aminotransferase elevation.

  • Open Access

    Explaining higher functional disability in women compared to men among older adults – the Singapore Chinese Health Study

    by Li Feng Tan, Aizhen Jin, Ariel Fangting Ying, An Pan, Gim Gee Teng, Woon-Puay Koh

    Studies suggest that the higher prevalence of functional disability in women could be explained by differences in social and health-related factors. We exa


  • Open Access

    Personalised Dosing Using the CURATE.AI Algorithm: Protocol for a Feasibility Study in Patients with Hypertension and Type II Diabetes Mellitus

    by Amartya Mukhopadhyay, Jennifer Sumner, Lieng Hsi Ling, Raphael Hao Chong Quek, Andre Teck Huat Tan, Gim Gee Teng, Santhosh Kumar Seetharaman, Satya Pavan Kumar Gollamudi, Dean Ho, Mehul Motani

    Chronic diseases typically require long-term management through healthy lifestyle practices and pharmacological intervention. Although efficacious treatments exist, disease control is often sub-optimal leading to chronic disease-related sequela. Poor disease control can partially be explained by the ‘one size fits all’ pharmacological approach. Precision medicine aims to tailor treatments to the individual. CURATE.AI is a dosing optimisation platform that considers individual factors to improve the precision of drug therapies. CURATE.AI has been validated in other therapeutic areas, such as cancer, but has yet to be applied in chronic disease care. We will evaluate the CURATE.AI system through a single-arm feasibility study (n = 20 hypertensives and n = 20 type II diabetics). Dosing decisions will be based on CURATE.AI recommendations. We will prospectively collect clinical and qualitative data and report on the clinical effect, implementation challenges, and acceptability of using CURATE.AI. In addition, we will explore how to enhance the algorithm further using retrospective patient data. For example, the inclusion of other variables, the simultaneous optimisation of multiple drugs, and the incorporation of other artificial intelligence algorithms. Overall, this project aims to understand the feasibility of using CURATE.AI in clinical practice. Barriers and enablers to CURATE.AI will be identified to inform the system’s future development.


  • Open Access

    Recommendations for COVID‐19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists

    by Amelia Santosa, Chuanhui Xu, Thaschawee Arkachaisri, Kok Ooi Kong, Aisha Lateef, Tau Hong Lee, Keng Hong Leong, Andrea Hsiu Ling Low, Melonie K. Sriranganathan, Teck Choon Tan, et al.

    Aim: People with rheumatic diseases (PRD) remain vulnerable in the era of the COVID‐19 pandemic. We formulated recommendations to meet the urgent need for a consensus for vaccination against SARS‐CoV‐2 in PRD.Methods: Systematic literature reviews were performed to evaluate: (a) outcomes in PRD with COVID‐19; (b) efficacy, immunogenicity and safety of COVID‐19 vaccination; and (c) published guidelines/recommendations for non‐live, non‐COVID‐19 vaccinations in PRD. Recommendations were formulated based on the evidence and expert opinion according to the Grading of Recommendations Assessment, Development and Evaluation methodology.Results: The consensus comprises 2 overarching principles and 7 recommendations. Vaccination against SARS‐CoV‐2 in PRD should be aligned with prevailing national policy and should be individualized through shared decision between the healthcare provider and patient. We strongly recommend that eligible PRD and household contacts be vaccinated against SARS‐CoV‐2. We conditionally recommended that the COVID‐19 vaccine be administered during quiescent disease if possible. Immunomodulatory drugs, other than rituximab, can be continued alongside vaccination. We conditionally recommend that the COVID‐19 vaccine be administered prior to commencing rituximab if possible. For patients on rituximab, the vaccine should be administered a minimum of 6 months after the last dose and/or 4 weeks prior to the next dose of rituximab. Post‐vaccination antibody titers against SARS‐CoV‐2 need not be measured. Any of the approved COVID‐19 vaccines may be used, with no particular preference.Conclusion: These recommendations provide guidance for COVID‐19 vaccination in PRD. Most recommendations in this consensus are conditional, reflecting a lack of evidence or low‐level evidence.


  • Open Access

    Recommendations for COVID-19 Vaccination in People with Rheumatic Disease: Developed by the Singapore Chapter of Rheumatologists

    by Amelia Santosa, Chuanhui Xu, Thaschawee Arkachaisri, Kok Ooi Kong, Aisha Lateef, Tau Hong Lee, Keng Hong Leong, Andrea Hsiu Ling Low, Melonie K Sriranganathan, Teck Choon Tan, et al.

    Aim People with rheumatic diseases (PRD) remain vulnerable in the era of the COVID-19 pandemic. We formulated recommendations to meet the urgent need for a consensus for vaccination against SARS-CoV-2 in PRD. Methods Systematic literature reviews were performed to evaluate (1) outcomes in PRD with COVID-19; (2) efficacy, immunogenicity and safety of COVID-19 vaccination; and (3) published guidelines/recommendations for non-live, non-COVID-19 vaccinations in PRD. Recommendations were formulated based on the evidence and expert opinion according to the Grading of Recommendations Assessment, Development and Evaluation methodology. Results The consensus comprises two overarching principles and seven recommendations. Vaccination against SARS-CoV-2 in PRD should be aligned with prevailing national policy and should be individualized through shared decision between the healthcare provider and patient. We strongly recommended that eligible PRD and household contacts be vaccinated against SARS-CoV-2. We conditionally recommended that the COVID-19 vaccine be administered during quiescent disease if possible. Immunomodulatory drugs, other than rituximab, can be continued alongside vaccination. We conditionally recommended that the COVID-19 vaccine be administered prior to commencing rituximab if possible. For patients on rituximab, the vaccine should be administered a minimum of 6 months after the last dose and/or 4 weeks prior to the next dose of rituximab. Post-vaccination antibody titres against SARS-CoV-2 need not be measured. Any of the approved COVID-19 vaccines may be used, with no particular preference. Conclusion These recommendations provide guidance for COVID-19 vaccination in PRD. Most recommendations in this consensus are conditional, reflecting a lack of evidence or low-level evidence. (words 247)

  • A nurse‐led, rheumatologist‐assisted telemedicine intervention for dose escalation of urate‐lowering therapy in gout

    by Kee Fong Phang, Amelia Santosa, Bernadette P. L. Low, Pamela S. H. Tan, Zhi Wei Khong, Anita Y. N. Lim, Gim Gee Teng, Sen Hee Tay

    Aims: Urate‐lowering therapy (ULT) is effective in gout, but suboptimal management with wide variability in dose escalation remains widespread. We protocolized dose escalation of ULT to improve gout management. The aim was to reduce time to achieve target serum urate (SU) <360 µmol/L.Methods: Process improvement tools were used to identify underlying causes of prolonged time to target SU. We designed a nurse‐led telemedicine intervention for dose escalation of ULT. Patients with gout with SU ≥360 µmol/L meeting indications for ULT at a single institution were recruited. Exclusion criteria were estimated glomerular filtration rate <30 mL/min, pregnancy, cognitive impairment and poor mobility. A nurse‐led telemedicine clinic was set up to perform patient education, monitoring of adverse events and drug escalation. We partnered with primary healthcare centers for routine blood tests.Results: From July 2016 to December 2017, 127 patients were recruited. Median time to target SU was 19.0 weeks (interquartile range [IQR] 11.0‐31.0). Median dose of allopurinol was 300 mg/d (IQR 200‐400) in normal renal function and lower in renal impairment. Median telemedicine calls required to achieve target SU was 2 (IQR 1‐3). No patient was hospitalized for gout flares. Two patients had adverse drug reactions, one required cessation of allopurinol for rash with eosinophilia, the other had self‐resolving ulcers and allopurinol was continued. Lower baseline SU and number of gout flares were associated with attainment of target SU.Conclusion: A nurse‐led telemedicine for gout care is effective and safe. Our results affirm the utility of telemedicine in increasing access to care and lower healthcare utilization.


  • Is HLA-B*58:01 Genotyping Cost Effective in Guiding Allopurinol use in Gout Patients with Chronic Kidney Disease?

    by Gim Gee Teng, Wei-Chuen Tan-Koi, Di Dong, Cynthia Sung

    Aim: Concerns for fatal severe cutaneous adverse reactions (SCARs) hamper allopurinol use. Methods and material: We adopted a health system perspective to evaluate the cost–effectiveness of HLA-B*5...


  • Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted‐synthetic therapy for the treatment of rheumatoid arthritis

    by Joanna Wai Yee Leong, Peter P. Cheung, Sajeewani Dissanayake, Warren Weng Seng Fong, Keng Hong Leong, Ying Ying Leung, Anita Yee Nah Lim, Nai Lee Lui, Mona Manghani, Amelia Santosa, et al.

    Introduction Approximately 30% of patients with rheumatoid arthritis (RA) respond inadequately to conventional‐synthetic disease‐modifying anti‐rheumatic drugs (csDMARDs). However, widespread use of biologic DMARDs (bDMARDs) and targeted‐synthetic (tsDMARDs) is limited by cost. We formulated updated recommendations for eligibility criteria for government‐assisted funding of bDMARDs/tsDMARDs for RA patients in Singapore. Materials and Methods Published guidelines regarding use of bDMARD and tsDMARDs were reviewed. We excluded those without a systematic literature review, formal consensus process or evidence grading. Separately, unpublished national reimbursement guidelines were included. Results Eleven recommendations regarding choice of disease activity measure, initiation, order of selection and continuation of bDMARD/tsDMARDs were formulated. A bDMARD/tsDMARD is indicated if a patient has: (a) at least moderately active RA with a Disease Activity Score in 28 joints/erythrocyte sedimentation rate (DAS28‐ESR) score of ≥3.2; (b) failed ≥2 csDMARD strategies, 1 of which must be a combination; (c) received an adequate dose regimen of ≥3 months for each strategy. For the first‐line bDMARD/tsDMARD, either tumor necrosis factor inhibitors (TNFi), non‐TNFi (abatacept, tocilizumab, rituximab), or tsDMARDs, may be considered. If a first‐line TNFi fails, options include another TNFi, non‐TNFi biologic or tsDMARDs. If a first‐line non‐TNFi biologic or tsDMARD fails, options include TNFi or another non‐TNF biologic or tsDMARD. For continued bDMARD/tsDMARD subsidization, a patient must have a documented DAS28‐ESR every 3 months and at least a moderate European League Against Rheumatism response by 6 months. Conclusion These recommendations are useful for guiding funding decisions, making bDMARD/tsDMARDs usage accessible and equitable in RA patients who fail csDMARDs.


  • Singapore chapter of rheumatologists' updated consensus statement on the eligibility for government subsidization of biologic and targeted therapy for the treatment of psoriatic arthritis

    by Cheryl K. T. Chua, Gim Gee Teng, Peter P. Cheung, Warren Weng Seng Fong, Keng Hong Leong, Ying Ying Leung, Anita Y. N. Lim, Nai Lee Lui, Mona Manghani, Amelia Santosa, et al.

    Aim: There have been major advances in biologic treatment options for psoriatic arthritis (PsA) since the publication of the 2015 consensus recommendations by the Chapter of Rheumatologists, College of Physicians, Academy of Medicine, Singapore, for government‐assisted funding, thus warranting a revision of this guideline.Methods: Recent trials and nine published guidelines on the use of biologic therapy for PsA were reviewed. Based on the synthesized evidence, a task force panel (TFP), consisting of 10 practicing rheumatologists in Singapore, rated the statements pertaining to the use of biologic therapy, using a modified Delphi approach. Consensus was obtained if >70% agreed on a statement.Results: The TFP agreed on 10 recommendations pertaining to the initiation, choice and continuation of biologic therapy. A biologic is indicated in patients with PsA: (a) with at least three swollen and tender joints, digits or entheses; and (b) who have failed at least two conventional synthetic disease‐modifying anti‐rheumatic drug (csDMARD) strategies for a minimum of 3 months each. Any approved drug class including tumor necrosis factor inhibitors, interleukin‐17 inhibitors (IL‐17i), IL‐12/23i or targeted synthetic DMARDs may be considered as first‐line treatment, and continued only if a response is achieved by 6 months.Conclusion: These recommendations developed through a formal consensus method may be useful to guide funding considerations for appropriate and equitable use of biologic therapy for eligible patients with PsA.